Table 4 The results of immunological response and clinical outcomes
Recurrence TTP c (day) | Death c (day) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
Patient no. | Lymphocyte proliferation a | IL-10 change (%) b | TGF- β change (%) b | VEGF change (%) b | AFP change (%) b | PIVKA-II change (%) b | SP | FU | SP | FU |
01 | Positive | 14.7 | 4.1 | 4.0 | −23.0 | 7.7 | No | No | No | No |
02 | Positive | −16.8 | −16.6 | −6.8 | −21.1 | 31.6 | No | No | No | No |
03 | Positive | 26.2 | −15.8 | −3.2 | −47.5 | 52.6 | No | Yes (294/217) | No | Yes (878/801) |
04 | Positive | −20.9 | 35.2 | 6.9 | 8.6 | 0.0 | No | Yes (1075/963) | No | No |
05 | Positive | 98.1 | 3.5 | −2.1 | 25.9 | 12.5 | No | Yes (917/805) | No | No |
06 | Positive | −13.3 | 59.2 | 36.8 | −21.5 | 0.0 | No | No | No | No |
07 | Positive | −22.4 | −32.3 | 42.3 | 63.6 | 37.0 | Yes (134/61) | — | No | Yes (340/267) |
08d | Positive | −23.7 | 49.5 | −17.6 | −10.3 | −28.6 | No | No | No | No |
09d | Positive | 70.8 | −66.8 | −5.6 | 569.1 | 1619.6 | Yes (205/91) | — | No | Yes (312/198) |
10 | Positive | 8.3 | 8.6 | −36.8 | −30.8 | 13.3 | No | Yes (1226/1037) | No | No |
11 | Negative | −12.4 | −7.5 | 226.0 | −16.7 | 44.4 | No | No | No | No |
12 | Positive | 26.0 | 20.7 | −24.0 | 25.0 | 122.2 | Yes (259/139) | — | No | Yes (783/663) |
